{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:32:27Z","timestamp":1790573547236,"version":"4.1.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11864-025-01323-7","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T10:25:25Z","timestamp":1745922325000},"page":"465-475","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Advances in Targeted Therapy for Metastatic Prostate Cancer"],"prefix":"10.1007","volume":"26","author":[{"given":"Kabir","family":"Grewal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya B.","family":"Dorff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar S.","family":"Mukhida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"issue":"1","key":"1323_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. (2024) Cancer statistics, 2024. CA: Cancer J Clinicians. 2024;74(1):12\u201349.","journal-title":"CA: Cancer J Clinicians"},{"issue":"5","key":"1323_CR2","first-page":"277","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA: Cancer J Clinicians. 2010;60(5):277\u2013300.","journal-title":"CA: Cancer J Clinicians"},{"key":"1323_CR3","doi-asserted-by":"crossref","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules. 2022;27(17).","DOI":"10.3390\/molecules27175730"},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"e390166","DOI":"10.1200\/EDBK_390166","volume":"43","author":"AA Hamid","year":"2023","unstructured":"Hamid AA, Sayegh N, Tombal B, Hussain M, Sweeney CJ, Graff JN, et al. Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment. Am Soc Clin Oncol Educ Book. 2023;43:e390166.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"1323_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41391-023-00725-8","volume":"27","author":"SJ Freedland","year":"2024","unstructured":"Freedland SJ, Davis M, Epstein AJ, Arondekar B, Ivanova JI. Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. Prostate Cancer Prostatic Dis. 2024;27(2):327\u201333.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"1323_CR6","first-page":"155","volume":"103","author":"CEP Smith","year":"2021","unstructured":"Smith CEP, Prasad V. Targeted Cancer Therapies. Am Fam Physician. 2021;103(3):155\u201363.","journal-title":"Am Fam Physician"},{"issue":"10","key":"1323_CR7","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. (2023) Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"key":"1323_CR8","doi-asserted-by":"publisher","first-page":"1159557","DOI":"10.3389\/fonc.2023.1159557","volume":"13","author":"AK Taylor","year":"2023","unstructured":"Taylor AK, Kosoff D, Emamekhoo H, Lang JM, Kyriakopoulos CE. PARP inhibitors in metastatic prostate cancer. Front Oncol. 2023;13:1159557.","journal-title":"Front Oncol"},{"issue":"5","key":"1323_CR9","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/s43018-023-00539-6","volume":"4","author":"MK Bakht","year":"2023","unstructured":"Bakht MK, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen JA, Kalidindi TM, et al. Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. Nat Cancer. 2023;4(5):699\u2013715.","journal-title":"Nat Cancer"},{"issue":"4","key":"1323_CR10","first-page":"227","volume":"20","author":"NM Hawkey","year":"2022","unstructured":"Hawkey NM, Sartor AO, Morris MJ, Armstrong AJ. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches. Clin Adv Hematol Oncol. 2022;20(4):227\u201338.","journal-title":"Clin Adv Hematol Oncol"},{"issue":"12","key":"1323_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","journal-title":"N Engl J Med"},{"issue":"1","key":"1323_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, Sayar E, Roudier MP, Patel RA, Coleman IM, De Sarkar N, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates. NPJ Precis Oncol. 2024;8(1):104.","journal-title":"NPJ Precis Oncol"},{"key":"1323_CR13","doi-asserted-by":"crossref","unstructured":"Zhang J, Chadha JS. Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies. Cancers (Basel). 2024;16(17).","DOI":"10.3390\/cancers16173098"},{"issue":"3","key":"1323_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","volume":"21","author":"M B\u00e9k\u00e9s","year":"2022","unstructured":"B\u00e9k\u00e9s M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21(3):181\u2013200.","journal-title":"Nat Rev Drug Discov"},{"issue":"7873","key":"1323_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583\u20139.","journal-title":"Nature"},{"issue":"4","key":"1323_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","volume":"60","author":"MJ O'Connor","year":"2015","unstructured":"O\u2019Connor MJ. Targeting the DNA Damage Response in Cancer. Mol Cell. 2015;60(4):547\u201360.","journal-title":"Mol Cell"},{"key":"1323_CR17","unstructured":"FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer [press release]. FDA.gov, 5\/20\/20 2020."},{"issue":"22","key":"1323_CR18","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","volume":"382","author":"J de Bono","year":"2020","unstructured":"de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020;382(22):2091\u2013102.","journal-title":"N Engl J Med"},{"issue":"3","key":"1323_CR19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.eururo.2023.05.021","volume":"84","author":"W Abida","year":"2023","unstructured":"Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023;84(3):321\u201330.","journal-title":"Eur Urol"},{"issue":"8","key":"1323_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","volume":"388","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Piulats JM, Reaume MN, Ostler P, McDermott R, Gingerich JR, et al. Rucaparib or Physician\u2019s Choice in Metastatic Prostate Cancer. N Engl J Med. 2023;388(8):719\u201332.","journal-title":"N Engl J Med"},{"issue":"5","key":"1323_CR21","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1200\/JCO.23.01868","volume":"42","author":"J Fallah","year":"2024","unstructured":"Fallah J, Xu J, Weinstock C, Brave MH, Bloomquist E, Fiero MH, et al. FDA Approval Summary: Olaparib in Combination With Abiraterone for Treatment of Patients With <i>BRCA<\/i>-Mutated Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2024;42(5):605\u201313.","journal-title":"J Clin Oncol"},{"key":"1323_CR22","doi-asserted-by":"crossref","unstructured":"Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. NEJM Evidence. 2022;1(9):EVIDoa2200043.","DOI":"10.1056\/EVIDoa2200043"},{"issue":"10398","key":"1323_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal N, Azad AA, Carles J, Fay AP, Matsubara N, Heinrich D, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10398):291\u2013303.","journal-title":"Lancet"},{"issue":"18","key":"1323_CR24","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1200\/JCO.22.01649","volume":"41","author":"KN Chi","year":"2023","unstructured":"Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, et al. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2023;41(18):3339\u201351.","journal-title":"J Clin Oncol"},{"issue":"11","key":"1323_CR25","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","volume":"3","author":"WR Polkinghorn","year":"2013","unstructured":"Polkinghorn WR, Parker JS, Lee MX, Kass EM, Spratt DE, Iaquinta PJ, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3(11):1245\u201353.","journal-title":"Cancer Discov"},{"issue":"13","key":"1323_CR26","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.1158\/1078-0432.CCR-18-0968","volume":"25","author":"PG Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PG, Gay CM, Byers LA, O\u2019Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clin Cancer Res. 2019;25(13):3759\u201371.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"1323_CR27","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","volume":"24","author":"F Saad","year":"2023","unstructured":"Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(10):1094\u2013108.","journal-title":"Lancet Oncol"},{"key":"1323_CR28","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad A, Carles J, Fay AP, Matsubara N, Szczylik C, et al. Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. J Clin Oncol. 2025;43(5_suppl):LBA18-LBA.","DOI":"10.1200\/JCO.2025.43.5_suppl.LBA18"},{"key":"1323_CR29","doi-asserted-by":"crossref","unstructured":"Agarwal N, Azad A, Fizazi K, Mateo J, Matsubara N, Shore ND, et al. Talapro-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo plus enza in patients with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC). Journal of Clinical Oncology. 2022;40(6_suppl):TPS221-TPS.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS221"},{"key":"1323_CR30","doi-asserted-by":"crossref","unstructured":"Rathkopf DE, Chi KN, Olmos D, Cheng HH, Agarwal N, Graff JN, et al. AMPLITUDE: A study of niraparib in combination with abiraterone acetate plus prednisone (AAP) versus AAP for the treatment of patients with deleterious germline or somatic homologous recombination repair (HRR) gene-altered metastatic castration-sensitive prostate cancer (mCSPC). J Clin Oncol. 2021;39(6_suppl):TPS176-TPS.","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS176"},{"issue":"362","key":"1323_CR31","doi-asserted-by":"publisher","first-page":"362ps17","DOI":"10.1126\/scitranslmed.aaf9246","volume":"8","author":"Y Pommier","year":"2016","unstructured":"Pommier Y, O\u2019Connor MJ, de Bono J. Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action. Sci Transl Med. 2016;8(362):362ps17.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1323_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13073-024-01370-z","volume":"16","author":"A Herencia-Ropero","year":"2024","unstructured":"Herencia-Ropero A, Llop-Guevara A, Staniszewska AD, Dom\u00e8nech-Viv\u00f3 J, Garc\u00eda-Galea E, Moles-Fern\u00e1ndez A, et al. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1\/2-associated cancer models. Genome Med. 2024;16(1):107.","journal-title":"Genome Med"},{"key":"1323_CR33","doi-asserted-by":"crossref","unstructured":"Yap T, Im S-A, Schram A, Sharp A, Balmana J, Baird R, editors. First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1\/2, PALB2 or RAD51C\/D mutations. Cancer Research; 2022.","DOI":"10.1158\/1538-7445.AM2022-CT007"},{"key":"1323_CR34","doi-asserted-by":"crossref","unstructured":"Azad A, Voskoboynik M, Joshua AM, Weickhardt AJ, Sankey P, Pacey S, et al. PETRANHA: Phase 1\/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer\u2013Interim safety and pharmacokinetic results. J Clin Oncol. 2024;42(4_suppl):123-.","DOI":"10.1200\/JCO.2024.42.4_suppl.123"},{"key":"1323_CR35","doi-asserted-by":"crossref","unstructured":"Chi KN, Agarwal N, Armstrong AJ, Hellmis E, Schl\u00fcrmann F, Sugimoto M, et al. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with new hormonal agents in patients with metastatic castration-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). J Clin Oncol. 2024;42(16_suppl):TPS5123-TPS.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5123"},{"issue":"1","key":"1323_CR36","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","volume":"12","author":"L Mei","year":"2019","unstructured":"Mei L, Zhang J, He K, Zhang J. Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. J Hematol Oncol. 2019;12(1):43.","journal-title":"J Hematol Oncol"},{"issue":"22","key":"1323_CR37","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.4161\/15384101.2014.960729","volume":"13","author":"Y Cui","year":"2014","unstructured":"Cui Y, Palii SS, Innes CL, Paules RS. Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents. Cell Cycle. 2014;13(22):3541\u201350.","journal-title":"Cell Cycle"},{"key":"1323_CR38","doi-asserted-by":"crossref","unstructured":"Reichert ZR, Devitt ME, Alumkal JJ, Smith DC, Caram MV, Palmbos P, et al. Targeting resistant prostate cancer, with or without DNA repair defects, using the combination of ceralasertib (ATR inhibitor) and olaparib (the TRAP trial). J Clin Oncol. 2022;40(6_suppl):88-.","DOI":"10.1200\/JCO.2022.40.6_suppl.088"},{"issue":"17","key":"1323_CR39","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang Z, Pili\u00e9 PG, Geng C, Manyam GC, Yang G, Park S, et al. ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate Cancer. Clin Cancer Res. 2021;27(17):4898\u2013909.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1323_CR40","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdz192","volume":"30","author":"J Mateo","year":"2019","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balma\u00f1a J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30(9):1437\u201347.","journal-title":"Ann Oncol"},{"issue":"26","key":"1323_CR41","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the Androgen Signaling Axis in Prostate Cancer. J Clin Oncol. 2023;41(26):4267\u201378.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1323_CR42","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cell.2018.05.037","volume":"174","author":"DY Takeda","year":"2018","unstructured":"Takeda DY, Spis\u00e1k S, Seo JH, Bell C, O\u2019Connor E, Korthauer K, et al. A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer. Cell. 2018;174(2):422-32.e13.","journal-title":"Cell"},{"key":"1323_CR43","doi-asserted-by":"crossref","unstructured":"Zhu X, Farsh T, Vis D, Yu I, Li H, Liu T, et al. Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer. J Clin Invest. 2024;134(19).","DOI":"10.1172\/JCI178604"},{"issue":"4","key":"1323_CR44","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","volume":"20","author":"D Chirnomas","year":"2023","unstructured":"Chirnomas D, Hornberger KR, Crews CM. Protein degraders enter the clinic - a new approach to cancer therapy. Nat Rev Clin Oncol. 2023;20(4):265\u201378.","journal-title":"Nat Rev Clin Oncol"},{"key":"1323_CR45","doi-asserted-by":"crossref","unstructured":"Gao X, Burris Iii HA, Vuky J, Dreicer R, Sartor AO, Sternberg CN, et al. Phase 1\/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 40(6_suppl):17-.","DOI":"10.1200\/JCO.2022.40.6_suppl.017"},{"key":"1323_CR46","doi-asserted-by":"crossref","unstructured":"Petrylak DP, McKean M, Lang JM, Gao X, Dreicer R, Geynisman DM, et al. ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2 study. J Clin Oncol. 2024;42(16_suppl):5011-.","DOI":"10.1200\/JCO.2024.42.16_suppl.5011"},{"issue":"1","key":"1323_CR47","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.annonc.2024.09.005","volume":"36","author":"DE Rathkopf","year":"2025","unstructured":"Rathkopf DE, Patel MR, Choudhury AD, Rasco D, Lakhani N, Hawley JE, et al. Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2025;36(1):76\u201388.","journal-title":"Ann Oncol"},{"key":"1323_CR48","doi-asserted-by":"crossref","unstructured":"Fizazi K, Bernard-Tessier A, Roubaud G, Utriainen T, Barth\u00e9l\u00e9my P, Fl\u00e9chon A, et al. Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer. NEJM Evid. 2024;3(1):EVIDoa2300171.","DOI":"10.1056\/EVIDoa2300171"},{"key":"1323_CR49","doi-asserted-by":"crossref","unstructured":"Raina K, Eastman KJ, Yu X, Forbes CD, Jones KM, Mousseau JJ, et al. An oral androgen receptor RIPTAC for prostate cancer. Journal of Clinical Oncology. 2023;41(6_suppl):184-.","DOI":"10.1200\/JCO.2023.41.6_suppl.184"},{"issue":"28","key":"1323_CR50","doi-asserted-by":"publisher","first-page":"e2322203121","DOI":"10.1073\/pnas.2322203121","volume":"121","author":"S Zaidi","year":"2024","unstructured":"Zaidi S, Park J, Chan JM, Roudier MP, Zhao JL, Gopalan A, et al. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen\u2013targeted therapies. Proc Natl Acad Sci. 2024;121(28):e2322203121.","journal-title":"Proc Natl Acad Sci"},{"issue":"10231","key":"1323_CR51","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208\u201316.","journal-title":"Lancet"},{"issue":"9","key":"1323_CR52","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023;29(9):1651\u20137.","journal-title":"Clin Cancer Res"},{"issue":"10459","key":"1323_CR53","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. <sup>177<\/sup>Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. The Lancet. 2024;404(10459):1227\u201339.","journal-title":"The Lancet"},{"issue":"2","key":"1323_CR54","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(23)00638-1","volume":"25","author":"MM Sathekge","year":"2024","unstructured":"Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al. Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study. Lancet Oncol. 2024;25(2):175\u201383.","journal-title":"Lancet Oncol"},{"key":"1323_CR55","doi-asserted-by":"crossref","unstructured":"Morris MJ, Wong JYC, Nordquist L, Szmulewitz RZ, Agarwal N, Attiyeh EF, et al. A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2024;42(16_suppl):5010-.","DOI":"10.1200\/JCO.2024.42.16_suppl.5010"},{"key":"1323_CR56","doi-asserted-by":"publisher","first-page":"175628722311822","DOI":"10.1177\/17562872231182219","volume":"15","author":"KK Zarrabi","year":"2023","unstructured":"Zarrabi KK, Narayan V, Mille PJ, Zibelman MR, Miron B, Bashir B, et al. Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer. Ther Adv Urol. 2023;15:17562872231182220.","journal-title":"Ther Adv Urol"},{"issue":"2","key":"1323_CR57","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2217\/imt-2020-0256","volume":"13","author":"HD Hummel","year":"2021","unstructured":"Hummel HD, Kufer P, Gr\u00fcllich C, Seggewiss-Bernhardt R, Deschler-Baier B, Chatterjee M, et al. Pasotuxizumab, a BiTE(\u00ae) immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings. Immunotherapy. 2021;13(2):125\u201341.","journal-title":"Immunotherapy"},{"issue":"3","key":"1323_CR58","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","volume":"21","author":"EA Lim","year":"2023","unstructured":"Lim EA, Schweizer MT, Chi KN, Aggarwal R, Agarwal N, Gulley J, et al. Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2023;21(3):366\u201375.","journal-title":"Clin Genitourin Cancer"},{"issue":"8","key":"1323_CR59","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","volume":"30","author":"T Dorff","year":"2024","unstructured":"Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, et al. A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024;30(8):1488\u2013500.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1323_CR60","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1038\/s41467-023-37874-2","volume":"14","author":"V Bhatia","year":"2023","unstructured":"Bhatia V, Kamat NV, Pariva TE, Wu LT, Tsao A, Sasaki K, et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun. 2023;14(1):2041.","journal-title":"Nat Commun"},{"issue":"1","key":"1323_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","volume":"14","author":"WK Kelly","year":"2024","unstructured":"Kelly WK, Danila DC, Lin CC, Lee JL, Matsubara N, Ward PJ, et al. Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024;14(1):76\u201389.","journal-title":"Cancer Discov"},{"key":"1323_CR62","unstructured":"A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer Janssen: Global Trial Finder; 2025 [Available from: https:\/\/globaltrialfinder.janssen.com\/trial\/cr108958."},{"key":"1323_CR63","doi-asserted-by":"publisher","first-page":"S1000","DOI":"10.1016\/j.annonc.2024.08.1740","volume":"35","author":"MN Stein","year":"2024","unstructured":"Stein MN, Graham LS, Baldini C, Vinceneux A, Kessler E, Runcie K, et al. 1659TiP A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer. Ann Oncol. 2024;35:S1000.","journal-title":"Ann Oncol"},{"key":"1323_CR64","doi-asserted-by":"crossref","unstructured":"Aggarwal RR, Rottey S, Bernard-Tessier A, Mellado-Gonzalez B, Kosaka T, Stadler WM, et al. Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC). J Clin Oncol. 2024;42(16_suppl):5012-.","DOI":"10.1200\/JCO.2024.42.16_suppl.5012"},{"key":"1323_CR65","doi-asserted-by":"crossref","unstructured":"Milowsky MI, Galsky MD, Morris MJ, Crona DJ, George DJ, Dreicer R, et al. Phase 1\/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urol Oncol. 2016;34(12):530.e15-.e21.","DOI":"10.1016\/j.urolonc.2016.07.005"},{"issue":"1","key":"1323_CR66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/pros.23922","volume":"80","author":"DP Petrylak","year":"2020","unstructured":"Petrylak DP, Vogelzang NJ, Chatta K, Fleming MT, Smith DC, Appleman LJ, et al. PSMA ADC monotherapy in patients with progressive metastatic castration-resistant prostate cancer following abiraterone and\/or enzalutamide: Efficacy and safety in open-label single-arm phase 2 study. Prostate. 2020;80(1):99\u2013108.","journal-title":"Prostate"},{"issue":"13","key":"1323_CR67","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1158\/1078-0432.CCR-20-4528","volume":"27","author":"JS de Bono","year":"2021","unstructured":"de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, et al. Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide. Clin Cancer Res. 2021;27(13):3602\u20139.","journal-title":"Clin Cancer Res"},{"issue":"36","key":"1323_CR68","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.19.00646","volume":"37","author":"DC Danila","year":"2019","unstructured":"Danila DC, Szmulewitz RZ, Vaishampayan U, Higano CS, Baron AD, Gilbert HN, et al. Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2019;37(36):3518\u201327.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1323_CR69","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.eururo.2022.09.004","volume":"83","author":"C Guo","year":"2023","unstructured":"Guo C, Figueiredo I, Gurel B, Neeb A, Seed G, Crespo M, et al. B7\u2013H3 as a Therapeutic Target in Advanced Prostate Cancer. Eur Urol. 2023;83(3):224\u201338.","journal-title":"Eur Urol"},{"key":"1323_CR70","doi-asserted-by":"crossref","unstructured":"Patel MR, Johnson ML, Falchook GS, Doi T, Friedman CF, Piha-Paul SA, et al. DS-7300 (B7-H3 DXd-ADC) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A subgroup analysis of a phase 1\/2 multicenter study. J Clin Oncol. 2022;40(6_suppl):87-.","DOI":"10.1200\/JCO.2022.40.6_suppl.087"},{"key":"1323_CR71","doi-asserted-by":"crossref","unstructured":"Jang S, Powderly JD, Spira AI, Bakkacha O, Loo D, Bohac GC, et al. Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. J Clin Oncol. 2021;39(15_suppl):2631-.","DOI":"10.1200\/JCO.2021.39.15_suppl.2631"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01323-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01323-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T07:03:22Z","timestamp":1748675002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01323-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01323-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,29]]},"assertion":[{"value":"14 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB and SSM have conflicts-of-interest to report. TBD reports consulting to Astella, AstraZeneca, Bayer, Blue Earth, Janssen, Novartis, and Pfizer. TBD reports institutional research funding from Amgen, AstraZeneca, and Abbvie. NA has no personal conflicts-of-interest since May 2021. In his lifetime, NA reports consulting to Astellas, AstraZeneca, AVEO, Bayer, Bristol Myers Squibb, Calithera, Clovis, Eisai, Eli Lilly, EMD Serono, Exelixis, Foundation Medicine, Genentech, Gilead, Janssen, Merck, MEI Pharma, Nektar, Novartis, Pfizer, Pharmacyclics, and Seattle Genetics. NA reports institutional funding from Arnivas, Astellas, AstraZeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, ORIC, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon. AWH reports consulting to Janssen, Intellisphere, AVEO, Exelixis, Eisai, Pfizer, and Tolmar; honoraria from Medscape, Binaytara Foundation, Projects in Knowledge, Curio Science, Dava Oncology, and Mashup Media; and institutional research funding from Bayer, Eisai, and Halda Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}